Brief Reports Open Access
Copyright ©The Author(s) 2004. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 15, 2004; 10(18): 2723-2726
Published online Sep 15, 2004. doi: 10.3748/wjg.v10.i18.2723
Ovarian hormone modulates 5-hydroxytryptamine 3 receptors mRNA expression in rat colon with restraint stress-induced bowel dysfunction
Tian-Jin Li, Bao-Ping Yu, Wei-Guo Dong, He-Sheng Luo, Long Xu, Mu-Qi Li, Department of Gastroenterology, Renmin Hospital, Wuhan University, Wuhan 430060, Hubei Province, China
Author contributions: All authors contributed equally to the work.
Supported by the Key Technologies Programme of Hubei, No. 2003AA304B12
Correspondence to: Dr. Bao-Ping Yu, Department of Gastroenterology, Renmin Hospital, Wuhan University, Wuhan 430060, Hubei Province, China. yubaoping62@yahoo.com.cn
Telephone: +86-27-88075814
Received: November 18, 2003
Revised: November 22, 2003
Accepted: January 15, 2004
Published online: September 15, 2004

Abstract

AIM: To examine the effects of ovarian hormone on the expression of 5-hydroxytryptamine 3 receptors (5-HT3R) in rat colon of restraint stress-induced bowel dysfunction.

METHODS: Twenty-four female Sprague-Dawley rats were randomly divided into three groups of 8 each: sham operation, ovariectomy (OVX) and ovariectomy with estrogen (E2) and progesterone (P) replacement therapy (OVX+E2+P). The rats were subjected to 1-h restraint stress 4 wk after operation. The changes of defecation were monitored by collection of fecal pellets. The gonadal steroids were measured in duplicate by radioimmunoassay (RIA). The expression of 5-HT3R mRNA in the colon was studied by RT-PCR.

RESULTS: Compared with sham group and OVX+E2+P group, OVX group showed increase in fecal pellets and decrease in the time of vitreous pellets excretion (P < 0.01). Serum levels of E2 and P were suppressed in OVX group and restored following treatment with ovarian steroids (P < 0.01), and the levels of 5-HT3R mRNA in the colon of ovariectomized rats were significantly increased, the expression of 5-HT3R mRNA was significantly decreased in hormone replacement therapy group (P < 0.01).

CONCLUSION: Ovarian hormone plays a role in the regulation of 5-HT3R expressions in restraint stress-induced bowel dysfunction of rats. The interactions between ovarian steroids and gastrointestinal tract may have major pathophysiological implications in 5-HT-related disorders, such as irritable bowel syndrome (IBS).




INTRODUCTION

IBS is characterized by intermittent or continuous abdominal pain and alterations in bowel patterns[1,2]. The syndrome is one of the most common gastrointestinal (GI) disorders seen in primary care and specialist practices[3,4]. There is a female-to-male ratio of 2/l in North American population studies of IBS[5], and epidemiologic surveys indicate that women seek health care services for IBS more frequently than men[4,6]. In menstruating women, symptoms are influenced by menstrual cycle. Peri- and postmenopausal women have a high prevalence of altered bowel function and IBS-like gastrointestinal complaints[7]. For many women, symptoms become amplified around the time of menses[8]. However, the exact mechanism (e.g. ovarian hormones, stress response) accounting for these cyclic changes is still unknown.

Studies suggested that the female sex steroid hormones, including estrogen and progesterone, could affect the myoelectric and mechanical activity of colonic smooth muscle in vitro. By geometric center method, estrogen and progesterone pretreatment of ovariectomized rats resulted in a significant decrease in colonic transit compared with untreated ovariectomized rats[9].

5-HT3R is a ligand-gated ion channel and probably involved in the modulation of colonic motility and visceral pain in the gut[10]. Clinically, 5-HT3R antagonists are important in the treatment of symptoms in IBS and more effective on diminishing bowel pattern symptom in women as compared to men[11]. Rat with wrap restraint stress is an appropriate animal model to study stress-related colonic dysfunction like IBS[12]. Previous studies have suggested that restraint stress results in an increase of fecal pellet output in rats via peripheral 5-HT3 receptors[13].

Earlier research has shown that E2 can suppress gastric motility response to thyrotropin-releasing hormone (TRH) and restraint stress in conscious rats[14], low dose of P (1 mg/kg) increased intestinal transit while higher dose (10-20 mg/kg) had no effect. Recently, it has been demonstrated that both forskolin and 17-beta-estradiol inhibit the function of 5-HT3R in a noncompetitive manner and that this inhibition is independent of cAMP levels[15]. Based on the research mentioned above, we suggested that this change, in part, be due to the increased activity of 5-HT3R innervating these organs. Therefore, we decided to assess whether both of these sex steroids could modulate mRNA expression of 5-HT3R in rat colon with restraint stress-induced colonic dysfunction and the potential mechanisms involved. Ovariectomized rats were treated with or without E2 and P in combination, after that changes in fecal pellets and the time of vitreous pellets output were assessed. Furthermore, we used RT-PCR to determine whether there was a decrease in 5-HT3R mRNA expression after treatment with sex steroids.

MATERIALS AND METHODS
Animals

Twenty-four adult female Sprague-Dawley rats (weighing 220-250 g), purchased from the Animal Department of Tongji Medical College, Huazhong University of Science and Technology were housed individually in a light and temperature controlled room with light-dark cycles of 12:12 h, where the temperature (24 ± 2 °C) and relative humidity (65%-70%) were kept constant. The animals were fed on a standard pellet diet, and food was withdrawn overnight before surgery and emptying experiments, but free access to water was allowed ad libitum. Experimental protocols followed standards and policies of the Animal Care and Use Committee, School of Medicine, Wuhan University.

Surgical procedures

Rats were housed for 7 d before experiments. At 6 wk of age, rats were randomly divided into three groups of eight each: sham-operated group, OVX group and OVX+E2+P group. Under aseptic conditions, bilateral ovariectomy or sham operation was performed under general anesthesia with ketamine (100 mg/kg, ip). For OVX, two dorsolateral incisions, in the skin and the peritoneum, were made and the ovaries and uterine horn removed. Sham operations consisted of skin and peritoneum incisions. After operation, animals were housed four per cage under previous conditions. On the same day, rats in OVX+E2+P group were subcutaneously injected a mixture of estradiol benzoate (E2, 5 µg/d) and progesterone (P, 0.2 mg/d). Four weeks after E2 and P combination treatment, wrap restraint stress experiments were performed in the three groups.

Restraint stress-induced bowel dysfunction

The method described by Williams et al[16] was used with slight modifications. Rats were acclimated to metal mesh cage placed on a tray for 5 h (9:00-14:00). After the acclimation, they were lightly anesthetized with ether. Then, their forelimbs were restrained with adhesive tapes (12.5 mm in width). The restrained limbs and thoracic trunk were wrapped with other adhesive tapes (50 mm in width). Immediately after those rats were returned to the cages, the number of feces dropped on the tray was counted 1 h after the wrapping. Test compounds were administered 1 h or 30 min before the restraint.

Hormone assays

The blood was collected from the heart of anesthetized animals and serum was separated by centrifugation at 1500 r/min for 20 min and kept at -70 °C until assayed for E2 and P.The gonadal steroids were measured in duplicate by radioimmunoassay using kits (Tianjin Depu Biotech). Aliquots of serum were added to tubes that had been coated with antibodies to steroid hormone followed by addition of 125I-hormone. Mixtures were vortexed gently and incubated for 2-3 h at room temperature. Incubation was terminated by aspirating excess of 125I-hormone and tubes were counted.

RNA extraction and RT-PCR

Distal colon tissues were harvested from animals in various treatment groups and frozen in liquid nitrogen. Total RNA from the frozen tissues was extracted using TRIzol as described by the manufacturer’s protocol (Invitrogen). RNA was dissolved in RNase-free water and the concentration was determined by measuring the optical density (A) at 260 nm. The purity of the RNA was assessed by the ratio of A260/A280. Two micrograms of total RNA from each sample was transcribed into cDNA using M-MLV reverse transcriptase (Promega). Briefly, total RNA was mixed with M-MLV reverse transcriptase (200 U/µL), oligo (dT)18 (50 µmol/L, Sangon, Shanghai), RNase inhibitor (40 U/µL), and dNTPs (1.25 mmol/L each, TaKaRa, Dalian) in a buffer containing 37.5 mmol/L KCl, 25 mmol/L Tris-HCl, and 1.5 mmol/L MgCl2 (pH8.3) in a total volume of 25 µL. The mixture was incubated at 42 °C for 90 min, heated to 95 °C for 5 min and cooled to 58 °C for 5 min. The resulted cDNA samples were amplified by PCR using Biometra PCR machine (Standard Power Pack P25, Germany) and the following specific primer pairs were used (SBS Genetech, Beijing): rats 5-HT3R sense, 5’-GAGACCATCTTCATTGTGCAGCTGGTGCA-3’; antisense, 5’-ACAGCAGCGTGTCCAGCACATATCCCACC-3’, for the 397-bp product[17]. Amplification of the rat β-actin gene transcript was used to control the efficiency of RT-PCR among the samples, β-actin sense, 5’-GTCACCCACACTGTGCCCATCT-3’; antisense, 5’-ACAGAGTACTTGCGCTCAGGAG-3’ for the 542-bp product[18]. PCR mixes contained 25 pmoL each of sense and antisense primers, 2.0 U Taq DNA polymerase (Biostar), the buffer supplemented with 1.5 mmol/L MgCl2, 0.2 mmol/L dNTPs and 1 µL cDNA in 25 µL. The amplification cycles were carried out under the following conditions: first denaturing at 94 °C for 3 min, then denaturing at 92 °C for 45 s, annealing at 55 °C for 45 s, and extension at 72 °C for 45 s for a total of 35 cycles, finally a 7 min extension at 72 °C was conducted. The resulted PCR products were analyzed on 20 g/L agarose gels in TBE buffer (40 mmol/L Tris-acetate, 1 mmol/L EDTA, pH8.3) containing 0.05 µg/mL ethidium bromide. Appropriate molecular weight markers (100 bp ladder, MBI) were used to verify the required size of the final PCR product. The gels were scanned and the mean density of the products were visualized and photographed under the BIO-PROFIL (VILBER LOURMAT, France).

Statistical analysis

Results are expressed as mean ± SD. The statistical significance of difference was evaluated with one-way analysis of variance (ANOVA), and analyzed by SPSS 10.0. A confidence level of P < 0.05 was considered significant.

RESULTS
Fecal pellets output

Table 1 shows the effects of E2+P combination and blank control on restraint stress-induced fecal pellet output in rats. The number of fecal pellets counted during observation period was negligible in unrestrained normal rats. In the restraint stress rats, fecal pellet output was measured with pellet counts of 5.6 ± 0.5 for ovarian hormone-induced sham group. The number of fecal pellets was significantly increased in OVX vehicle-treated group compared with sham and E2+P-treated group (vehicle-treated, 8.6 ± 0.6; sham group, 5.6 ± 0.5; E2+P-treated, 4.1 ± 0.5; P < 0.01). Meanwhile, the time of vitreous pellets output was significantly decreased (P < 0.01). The number of fecal pellets was significantly decreased (E2+P-treated, 4.1 ± 0.5; sham group, 5.6 ± 0.5; P < 0.01) and the time of vitreous pellets output was significantly increased in E2+P-treated group (P < 0.01).

Table 1 Effects of ovarian hormone on fecal pellets output in the ovariectomized restraint stress rats (mean ± SD, n = 8).
GroupFecal pellets (number)Time of vitreous pellet output (min)
Sham-operated5.6 ± 0.54.8 ± 0.26
OVX8.6 ± 0.6d1.3 ± 0.22f
OVX+E2+P4.1 ± 0.5db5.8 ± 0.29f
Serum concentration of estrogen and progesterone

As expected, serum levels of E2 were suppressed in OVX rats and restored after treatment with ovarian steroids (sham-operated, 104 ± 6; OVX: vehicle-treated 15.7 ± 0.8; E2+P-treated 168 ± 8; P < 0.01, Table 2). Serum levels of P were also decreased in OVX rats and increased following treatment with E2+P (sham-operated, 26 ± 1; OVX: vehicle-treated, 3.2 ± 0.6; E2+P-treated, 44 ± 2; P < 0.01).

Table 2 Serum concentration of estrogen and progesterone (mean ± SD, n = 8).
GroupE2 (pmol/L)P (nmol/L)
Sham-operated104 ± 626 ± 1
OVX15.7 ± 0.8d3.2 ± 0.6b
OVX+E2+P168 ± 8d44 ± 2b
Expression of 5-HT3R in the colon of restraint stressed rats

Effects of ovarian hormone on the expressions of 5-HT3R mRNA in colon tissues of restraint stress-induced rats were examined by RT-PCR as shown in Figure 1, which revealed a marked increase in OVX vehicle-treated group (relative optical density: 1.12 ± 0.07). The expression of 5-HT 3R mRNA in colon was increased to a maximum in OVX vehicle-treated group (sham: 0.85 ± 0.06, P < 0.01) and significantly decreased after E2+P-treatment (0.65 ± 0.05, P < 0.01, Figure 1B). Furthermore, 5-HT3R mRNA expression was decreased by 1.3-fold in E2+P-treated group (P < 0.01 compared with sham group, Figure 1B). However, there was a trend of lower expression of 5-HT3R mRNA in colon with the increasing serum levels of E2 and P.

Figure 1
Figure 1 A: 5-HT3R mRNA expression in the colon of restraint stress rats. Lane 1: Markers, 100-bp ladder; lane 2: sham-operated group; lane 3: OVX group; lane 4: OVX+E2+P group. B: 5-HT3R mRNA expression in the colon of restraint stress rats. The bar shows the relative optical density of 5-HT3R band obtained from different groups. Values were reported as the ratio of 5-HT3R to β-actin signals and normalized by the corresponding RT-PCR products for β-actin, used as the internal control. PCR was carried out for 35 cycles. Amplified cDNA products were separated by 20 g/L agarose gel electrophoresis. bP = 0.000 vs OVX group; dP = 0.000 vs sham-operated group.
DISCUSSION

IBS is a complex GI disorder with a poorly understood pathophysiology in which three major mechanisms interact: altered gastrointestinal motility, increased sensory function of the intestine and psychosocial factors[19]. Various observations suggested that fluctuations in sex hormones in women might have an influential role in IBS: for many women, symptoms became amplified around the time of menses[8]. In menstruating women, symptoms are influenced by menstrual cycle and bloating, abdominal pain, and diarrhea tend to be amplified during the late luteal and early menses phases[20,21]. GI symptoms increase and intestinal transit decreases during pregnancy (a time of high E2 and P levels)[22], and rectal sensitivity is greater during menses compared with other menstrual-cycles in women with IBS[8]. The precise mechanism responsible for the changes in gastrointestinal motility is still unknown. Earlier research has shown that E2 can delay gastric emptying and GI transit in rats[23], low dose of P (1 mg/kg, i.p.) enhanced the gastric emptying and high dose of P (5 mg/kg, i.p.) inhibited it. P (1 mg/kg) increased the intestinal transit while higher dose (10-20 mg/kg) had no effect. E2 suppresses gastric motility response to thyrotropin-releasing hormone (TRH) and restraint stress in conscious rats[14]. The precise sex steroid that is responsible for these changes is controversial. It appears that sex steroids play an important role in modulating these effects as postmenopausal women being treated with sex hormone-replacement therapy (HRT) had a decreased rate of gastric emptying of solids compared with men. In contrast, postmenopausal women without hormone replacement had rates of solid emptying similar to those of men[24]. Results in pre- and postmenopausal women taking sex HRT showed they had slower gastric emptying than men[25]. Whereas recent studies have also confirmed that HRT is associated with an increased risk of IBS[26].

Stress is known to be an important factor in causing IBS, since it significantly alters bowel functions. Several rodent models of bowel dysfunction caused by restraint stress have been investigated for pharmacological analysis of a stress-related bowel disorder like IBS[12,13,27]. There were similarities between the intestinal effects of wrap restraint stress in rats and IBS in human. Therefore, wrap restraint stress rat is an appropriate animal model to study stress-related intestinal dysfunction. The role of sex hormones in the development of IBS is the subject of ongoing study. Our results indicate that in the restraint stress rats, serum levels of E2 and P were suppressed in OVX rats and restored following chronic treatment with ovarian steroids. Meanwhile, OVX vehicle-treatment significantly increased the number of fecal pellets, moreover, the time of vitreous pellets output was significantly decreased. E2+P treatment significantly decreased the number of fecal pellets and increased the time of vitreous pellets output. Our study indicated that E2 and P could relieve the rat colon contractile response to restraint stress, thus decrease the number of fecal pellets and increase the number of fecal pellets output.

5-HT3R is expressed by most myenteric neurons, including those that excite gastrointestinal muscle[28-30]. In contrast to other serotonin receptor subtypes, these receptors are ligand-gated ion channels involved in rapid excitatory responses in peripheral and central nervous system[31]. 5-HT3R mediates a fast inward current in myenteric neurons[29,30], and their activation is thought to enhance cholinergic transmission via the release of acetylcholine from parasympathetic nerve terminals[13], thus resulting in an increase in gastrointestinal motility, fluid secretion and pain. Clinically, 5-HT3R antagonists are important in the treatment of symptoms in IBS[32].

Previous studies demonstrated that restraint stress resulted in an increase in fecal pellet output in rats fed the diet, as well as diarrhea in food-deprived rats, which are equally mediated through the endogenous activation of the 5-HT3R[13,14]. Clinically, 5-HT3R antagonist drugs appeared to more effectively diminish bowel pattern disruption in women with IBS as compared to men[11]. Recently, it has been demonstrated that both forskolin and 17-beta-estradiol inhibit the function of 5-HT3R in a noncompetitive manner and that this inhibition is independent of cAMP levels[15]. Because 5-HT3R plays a role in the pathogenesis of IBS, it is possible that the attenuated development of IBS in female rats might be related to the modulation of gonadal hormones on 5-HT3R and GI system. This study focused on the effects of gonadal steroid hormones on 5-HT3R mRNA expression in colon of wrap restraint stress rats. We observed an increase in 5-HT3R gene expression in OVX rats. The increase in 5-HT3R gene expression was prevented by treating the OVX rats with a combination of E2 and P. These results suggest that 5-HT3R mRNA expression is sensitive to the absence of E2 and P. Their roles in regulation of 5-HT3R mRNA expression deserve further study. If the increase in the density of 5-HT3R gene expression induced by E2 and P deficiency reflects overactivity of 5-HT3R, then such changes may be relevant to hormone- and age-related GI dysfunction.

In conclusion, we suggest that female gonadal hormones may play an important role in regulation of colon 5-HT3R. Exploration of 5-HT3R expression by gonadal steroid hormones could contribute to a better understanding of the interactions between ovarian steroids and GI and may have major pathophysiological implications for 5-HT-related bowel disorders, such as IBS.

Footnotes

Edited by Chen WW and Zhu LH Proofread by Xu FM

References
1.  Heitkemper M, Jarrett M. Irritable bowel syndrome: causes and treatment. Gastroenterol Nurs. 2000;23:256-263.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 3]  [Cited by in F6Publishing: 3]  [Article Influence: 0.1]  [Reference Citation Analysis (0)]
2.  Leahy A, Epstein O. Non-pharmacological treatments in the irritable bowel syndrome. World J Gastroenterol. 2001;7:313-316.  [PubMed]  [DOI]  [Cited in This Article: ]
3.  Olden KW. Diagnosis of irritable bowel syndrome. Gastroenterology. 2002;122:1701-1714.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 95]  [Cited by in F6Publishing: 106]  [Article Influence: 4.8]  [Reference Citation Analysis (0)]
4.  Foxx-Orenstein AE, Clarida JC. Irritable bowel syndrome in women: the physician-patient relationship evolving. J Am Osteopath Assoc. 2001;101:S12-S16.  [PubMed]  [DOI]  [Cited in This Article: ]
5.  Camilleri M. Management of the irritable bowel syndrome. Gastroenterology. 2001;120:652-668.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 224]  [Cited by in F6Publishing: 235]  [Article Influence: 10.2]  [Reference Citation Analysis (0)]
6.  Saito YA, Schoenfeld P, Locke GR. The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol. 2002;97:1910-1915.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 37]  [Cited by in F6Publishing: 38]  [Article Influence: 1.7]  [Reference Citation Analysis (0)]
7.  Triadafilopoulos G, Finlayson M, Grellet C. Bowel dysfunction in postmenopausal women. Women Health. 1998;27:55-66.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 41]  [Cited by in F6Publishing: 44]  [Article Influence: 1.7]  [Reference Citation Analysis (0)]
8.  Houghton LA, Lea R, Jackson N, Whorwell PJ. The menstrual cycle affects rectal sensitivity in patients with irritable bowel syndrome but not healthy volunteers. Gut. 2002;50:471-474.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 168]  [Cited by in F6Publishing: 161]  [Article Influence: 7.3]  [Reference Citation Analysis (0)]
9.  Ryan JP, Bhojwani A. Colonic transit in rats: effect of ovariectomy, sex steroid hormones, and pregnancy. Am J Physiol. 1986;251:G46-G50.  [PubMed]  [DOI]  [Cited in This Article: ]
10.  Hunt RH, Tougas G. Evolving concepts in functional gastrointestinal disorders: promising directions for novel pharmaceutical treatments. Best Pract Res Clin Gastroenterol. 2002;16:869-883.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 24]  [Cited by in F6Publishing: 26]  [Article Influence: 1.2]  [Reference Citation Analysis (0)]
11.  Viramontes BE, Camilleri M, McKinzie S, Pardi DS, Burton D, Thomforde GM. Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol. 2001;96:2671-2676.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 89]  [Cited by in F6Publishing: 94]  [Article Influence: 4.1]  [Reference Citation Analysis (0)]
12.  Li J, Liu X, Xie P, Gu Q, Li J, Zhang Y, Tang Z. [The regulation of calcium in the movement of colonic smooth muscle in wrap restraint stress rats]. Zhonghua Neike Zazhi. 2000;39:588-591.  [PubMed]  [DOI]  [Cited in This Article: ]
13.  Miyata K, Kamato T, Nishida A, Ito H, Yuki H, Yamano M, Tsutsumi R, Katsuyama Y, Honda K. Role of the serotonin3 receptor in stress-induced defecation. J Pharmacol Exp Ther. 1992;261:297-303.  [PubMed]  [DOI]  [Cited in This Article: ]
14.  Bond EF, Heitkemper MM, Bailey SL. Estrogen suppresses gastric motility response to thyrotropin-releasing hormone and stress in awake rats. Res Nurs Health. 1998;21:221-228.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in F6Publishing: 2]  [Reference Citation Analysis (0)]
15.  Oz M, Zhang L, Spivak CE. Direct noncompetitive inhibition of 5-HT(3) receptor-mediated responses by forskolin and steroids. Arch Biochem Biophys. 2002;404:293-301.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 26]  [Cited by in F6Publishing: 27]  [Article Influence: 1.2]  [Reference Citation Analysis (0)]
16.  Williams CL, Villar RG, Peterson JM, Burks TF. Stress-induced changes in intestinal transit in the rat: a model for irritable bowel syndrome. Gastroenterology. 1988;94:611-621.  [PubMed]  [DOI]  [Cited in This Article: ]
17.  Isenberg KE, Ukhun IA, Holstad SG, Jafri S, Uchida U, Zorumski CF, Yang J. Partial cDNA cloning and NGF regulation of a rat 5-HT3 receptor subunit. Neuroreport. 1993;5:121-124.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 44]  [Cited by in F6Publishing: 46]  [Article Influence: 1.5]  [Reference Citation Analysis (0)]
18.  Dou DB, Huang YW, Wang SP, Cai G, Lin J. Influence of Zhishi Xiaopi pill on gene expression of CCK and CCK-A receptor in upper-alimentary tract of rats.. Shijie Huaren Xiaohua Zazhi. 2002;10:927-930.  [PubMed]  [DOI]  [Cited in This Article: ]
19.  Camilleri M. Pathophysiology in irritable bowel syndrome. Drug News Perspect. 2001;14:268-278.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 10]  [Cited by in F6Publishing: 11]  [Article Influence: 0.5]  [Reference Citation Analysis (0)]
20.  Heitkemper MM, Jarrett M. Pattern of gastrointestinal and somatic symptoms across the menstrual cycle. Gastroenterology. 1992;102:505-513.  [PubMed]  [DOI]  [Cited in This Article: ]
21.  Heitkemper MM, Jarrett M, Cain KC, Shaver J, Walker E, Lewis L. Daily gastrointestinal symptoms in women with and without a diagnosis of IBS. Dig Dis Sci. 1995;40:1511-1519.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 39]  [Cited by in F6Publishing: 40]  [Article Influence: 1.4]  [Reference Citation Analysis (0)]
22.  Wald A, Van Thiel DH, Hoechstetter L, Gavaler JS, Egler KM, Verm R, Scott L, Lester R. Gastrointestinal transit: the effect of the menstrual cycle. Gastroenterology. 1981;80:1497-1500.  [PubMed]  [DOI]  [Cited in This Article: ]
23.  Bond EF, Heitkemper MM, Perigo R. Gastric emptying and gastric-intestinal transit in rats with varying ovarian hormone status. Nurs Res. 1996;45:218-224.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 20]  [Cited by in F6Publishing: 21]  [Article Influence: 0.8]  [Reference Citation Analysis (0)]
24.  Pérez Gutthann S, García Rodríguez LA, Castellsague J, Duque Oliart A. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. BMJ. 1997;314:796-800.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 248]  [Cited by in F6Publishing: 217]  [Article Influence: 8.0]  [Reference Citation Analysis (0)]
25.  Hutson WR, Roehrkasse RL, Wald A. Influence of gender and menopause on gastric emptying and motility. Gastroenterology. 1989;96:11-17.  [PubMed]  [DOI]  [Cited in This Article: ]
26.  Ruigómez A, García Rodríguez LA, Johansson S, Wallander MA. Is hormone replacement therapy associated with an increased risk of irritable bowel syndrome. Maturitas. 2003;44:133-140.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 40]  [Cited by in F6Publishing: 43]  [Article Influence: 2.0]  [Reference Citation Analysis (0)]
27.  Muraoka M, Mine K, Kubo C. A study of intestinal dysfunction induced by restraint stress in rats. Scand J Gastroenterol. 1998;33:806-810.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 10]  [Cited by in F6Publishing: 9]  [Article Influence: 0.3]  [Reference Citation Analysis (0)]
28.  Glatzle J, Sternini C, Robin C, Zittel TT, Wong H, Reeve JR, Raybould HE. Expression of 5-HT3 receptors in the rat gastrointestinal tract. Gastroenterology. 2002;123:217-226.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 126]  [Cited by in F6Publishing: 130]  [Article Influence: 5.9]  [Reference Citation Analysis (0)]
29.  Zhai J, Gershon MD, Walsh JH, Wong HC, Kirchgessner AL. Inward currents in neurons from newborn guinea pig intestine: mediation by 5-hydroxytryptamine type 3 receptors. J Pharmacol Exp Ther. 1999;291:374-382.  [PubMed]  [DOI]  [Cited in This Article: ]
30.  Zhou X, Galligan JJ. Synaptic activation and properties of 5-hydroxytryptamine(3) receptors in myenteric neurons of guinea pig intestine. J Pharmacol Exp Ther. 1999;290:803-810.  [PubMed]  [DOI]  [Cited in This Article: ]
31.  Gutiérrez B, Arranz MJ, Huezo-Diaz P, Dempster D, Matthiasson P, Travis M, Munro J, Osborne S, Kerwin RW. Novel mutations in 5-HT3A and 5-HT3B receptor genes not associated with clozapine response. Schizophr Res. 2002;58:93-97.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 38]  [Cited by in F6Publishing: 37]  [Article Influence: 1.7]  [Reference Citation Analysis (0)]
32.  Camilleri M, Mayer EA, Drossman DA, Heath A, Dukes GE, McSorley D, Kong S, Mangel AW, Northcutt AR. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther. 1999;13:1149-1159.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 279]  [Cited by in F6Publishing: 269]  [Article Influence: 10.8]  [Reference Citation Analysis (0)]